While our results show that both UDCA and DHP dose-dependently reduced tumor growth in mouse LLC tumor models, we hypothesized that HVEM/BTLA blockade would be combined with FXR antagonists to provide additional therapeutic benefit in NSCLC, especially for the FXRhiPD-L1lo subgroup. This evidence concerns the gene BTLA and non-small cell lung carcinoma.